

Publications of the Eichmüller group since 2010

Members of the group are depicted in **bold face**. Asterisks (*) indicate equal contribution.

---- 2023----

- 1) Meyer M, Parpoulas C, Barthélémy T, Becker JP, Charoentong P, Lyu Y, Börsig S, Bulbuc N, Tessmer C, Weinacht L, Ibberson D, **Schmidt P, Pipkorn R, Eichmüller SB**, Steinberger P, Lindner K, Poschke IC, Platten M, Fröhling S, Riemer AB, Hassel J, Roberti MP, Jäger D, Zörnig I, and Momburg F (accepted) MediMer: A versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection. *Frontiers in Immunology* 14: 1294565.
- 2) **Kordaß T, Chao T-Y, Osen W, and Eichmüller SB** (2023) Novel microRNAs modulating ecto-5'-nucleotidase expression. *Frontiers in Immunology* 14.
- 3) **Pane AA, Kordaß T, Hotz-Wagenblatt A, Dickes E, Kopp-Schneider A, Will R, Seliger B, Osen W, and Eichmüller SB** (2023) miRNAs affecting the susceptibility of melanoma cells to CD8+ T cell-mediated cytotoxicity. *Clin Transl Med.* 13: e1186.
- 4) **Chao T-Y*, Kordaß T*, Osen W, and Eichmüller SB** (2023) SOX9 is a target of miR-134-3p and miR-224-3p in breast cancer cell lines. *Mol Cell Biochem* 478(2):305-315.

---- 2022----

- 5) **Hartmann L, Osen W, Eichmüller OL, Kordaß T, Furkel J, Dickes E, Reid C, Debus J, Brons S, Abdollahi A, Moustafa M, Rieken S, and Eichmüller SB** (2022) Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model. *Cancer Lett.* 500.
- 6) Kehl N, Kilian M, Michel J, **Wagner TR**, Uhrig S, Brobeil A, Sester LS, Blobner S, Steiger S, Hundemer M, Weinhold N, Rippe K, Fröhling S, **Eichmüller SB**, Bunse L, Müller-Tidow C, Goldschmidt H, Platten M, Raab MS, and Friedrich M (2022) IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. *Journal for ImmunoTherapy for Cancer* 10.
- 7) Kustermann M, Dasari P, Knape I, Keltsch E, Liu J, Pfluger S, **Osen W**, Holzmann K, Huber-Lang M, Debatin KM, and Strauss G (2022) Adoptively Transferred in vitro-Generated Myeloid-Derived Suppressor Cells Improve T-Cell Function and Antigen-Specific Immunity after Traumatic Lung Injury. *J Innate Immun* 1-18.
- 8) Hernández-Malmierca P, Vonficht D, Schnell A, Uckelmann HJ, Bollhagen A, Mahmoud MAA, Landua SL, Salm EVd, Trautmann CL, Raffel S, Grünschlager F, Lutz R, Ghosh M, Renders S, Correia N, Donato E, Dixon KO, Hirche C, Andresen C, Robens C, Werner PS, Boch T, **Eisel D, Osen W**, Pilz F, Przybylla A, Klein C, Buchholz F, Milsom MD, Essers MAG, **Eichmüller SB**, Hofmann W-K, Nowak D, Hübschmann D, Hundemer M, Thiede C, Bullinger L, Müller-Tidow C, Armstrong SA, Trumpp A, Kuchroo VK, and Haas S (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell Stem Cell* 29(5):760-75 e10 doi: 10.1016/j.stem.2022.04.007.
- 9) Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D, Löwer M, Sonner JK, Krämer C, Zaman J, Jung S, Breckwoldt MO, Willimsky G, **Eichmüller SB**, Deimling Av, Wick W, Sahm F, Platten M, and Bunse L (2022) T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas. *Clin Cancer Res* 28:378-389.

---- 2021----

- 10) Horak P et al. (2021) Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. *Cancer Discov* 11: 2780-2795.

- 11) Ran T, **Eichmüller SB***, **Schmidt P**, and Schlander M* (2021) Reply to: Comments on "Cost of decentralized CAR T cell production in an academic non-profit setting". *Int J Cancer* 148: 516-517.
- 12) Bozza M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, Zörnig I, Jäger D, **Schmidt P***, and Harbottle RP* (2021) A non-viral, non-integrating DNA Nanovector platform for the safe, rapid, and persistent manufacture of recombinant T Cells. *Science Advances* 7: eabf1333.

---- 2020----

- 13) **Hartmann L**, **Schröter P**, **Osen W**, Baumann D, Offringa R, Moustafa M, Will R, Debus J, Brons S, Rieken S, and **Eichmüller SB** (2020) Photon versus carbon ion irradiation – immunomodulatory effects exerted on various murine tumor cell lines. *Scientific Reports* 10:21517.
- 14) Zhao X, Yang F, Mariz F, **Osen W**, Ottonello S, Bolchi A, and Müller M (2020) Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine. *Plos Pathogens* 16:e1008827.
- 15) Ran T, **Eichmüller SB***, **Schmidt P**, and Schlander M* (2020) Cost of decentralized CAR T cell production in an academic non-profit setting. *Int J Cancer* 147: 3438-3445.
- 16) Busch E, Kubon KD, Mayer JKM, Pidelaserra-Martí G, Albert J, Hoyler B, Heidbuechel JPW, Stephenson KB, Lichty BD, **Osen W**, **Eichmüller SB**, Jäger D, Ungerechts G, and Engeland CE (2020) Measles vaccines designed for enhanced CD8+ T cell activation. *Viruses* 12:242.
- 17) Hörhold F*, **Eisel D***, Oswald M, Kolte A, Röhl D, **Osen W**, **Eichmüller SB**, and König R (2020) Reprogramming of macrophages employing gene regulatory and metabolic network models. *PLOS Computational Biology* 16: e1007657.
- 18) **Schröter P**, **Hartmann L**, **Osen W**, Baumann D, Offringa R, Eisel D, Debus J, **Eichmüller SB***, and Rieken S* (2020) Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line. *Scientific Reports* 10:686.

---- 2019----

- 19) **Das K**, **Eisel D**, **Vormehr M**, Müller-Decker K, **Hommertgen A**, Jäger D, Zörnig I, Feuerer M, Kopp-Schneider A, **Osen W**, and **Eichmüller SB** (2019) A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice. *BMC Cancer* 19:914.
- 20) Poos AM, **Kordaß T**, Kolte A, Ast V, Oswald M, Rippe K, and König R (2019) Applying MIPRIP 2.0: Modelling TERT regulation across 19 different cancer types. *BMC Bioinformatics* 20: 737.
- 21) Katsanovskaja K, Driver T, **Pipkorn R**, and Edelson-Averbukh M (2019) Negative Ion Mode Collision-Induced Dissociation for Analysis of Protein Arginine Methylation. *J Am Soc Mass Spectrom* 30: 1229-1241.
- 22) Gangkofner DS, Holzinger D, Schröder L, **Eichmüller SB**, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende C, Dyckhoff G, Boscolo-Rizzo P, Ezic J, Marienfeld RB, Möller P, Völkel G, Kraus J, Kestler H, Brunner C, Schuler PJ, Wigand M, Theodoraki MN, Döscher J, Hoffmann TK, Pawlita M, Waterboer T, and Laban S (2019) Patterns of antibody responses to non-viral cancer antigens in head and neck squamous cell carcinoma patients differ by Human papillomavirus status. *Int J Cancer* 145, 3436-3444.
- 23) Laban S, Gangkofner DS, Holzinger D, Schroeder L, **Eichmüller SB**, Zörnig I, Jäger D, Wichmann G, Dietz A, Broglie MA, Herold-Mende C, Dyckhoff G, Boscolo-Rizzo P, Ezic RB, Marienfeld RB, Möller P, Völkel G, Kraus J, Kestler H, Brunner C, Schuler PJ, Wigand M, Theodoraki MN, Döscher J, Hoffmann TK, Pawlita M, Waterboer T, and Butt J (epub)

Antibody responses to cancer antigens identify patients with a poor prognosis among HPV-positive and HPV-negative head and neck squamous cell carcinoma patients. *Clin Cancer Res* 25: 7405-7412.

- 24) **Eisel D, Das K, Dickes E, König R, Osen W, and Eichmüller SB** (2019) Cognate interaction with CD4+ T cells instructs tumor-associated macrophages to acquire M1-like phenotype. *Front Immunol* 10(219).
- 25) Sharbi-Yunger A, Grees M, Gal C, Bassan D, **Eichmüller SB**, Tzehoval E, Utikal J, Umansky V, and Eisenbach L (2019) A universal anti-cancer vaccine: chimeric invariant chain potentiates the inhibition of melanoma progression and improvement of survival. *Int J Cancer* 144: 909-921.

---- 2018----

- 26) Ast V*, **Kordaß T***, Oswald M, Kolte A, **Eisel D, Osen W, Eichmüller SB**, Berndt A, and König R (2018) Piecewise linear regression identifies miR-192, miR-200c and miR-17 as fibroblast-mediated inhibitors of colorectal cancer invasion. *Oncotarget* 9(85): 35559-35580.
- 27) **Kordaß T, Weber CEM, Eisel D, Pane AA, Osen W, and Eichmüller SB** (2018) miR-193b and miR-30c-1* inhibit, whereas miR-576-5p enhances melanoma cell invasion. *Oncotarget* 9(65): 32507-32522.
- 28) **Kordaß T, Osen W, and Eichmüller SB** (2018) Controlling the immune suppressor: transcription factors and miRNAs regulating CD73/NT5E. *Frontiers in Immunology*, 9(813).
- 29) Grees M, Sharbi-Yunger A, Evangelou C, Baumann D, Cafri G, Tzehoval E, **Eichmüller SB**, Offringa R, Utikal J, Eisenbach L, and Umansky V (2018) Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. *Oncolimmunology* 7: e1445457.
- 30) Michels J, Becker N, Suciú S, Kaiser I, Benner A, Kosaloglu-Yalcin Z, Agoussi S, Halama N, Pawlita M, Waterboer T, **Eichmüller SB**, Jäger D, Eggermont AMM, and Zörnig I (accepted) Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC 18961 trial. *Oncolimmunology* 7: e1428157.
- 31) Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, **Eichmüller SB**, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels WS, and Schüssler-Lenz M (2018) Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies - the German Cancer Consortium approach. *Cancer Immunol Immun* 67(4):513-523.
- 32) Lv N, Hao S, **Luo C, Abukiwan A**, Hao Y, Gai F, Huang W, Huang L, Xiao X, **Eichmüller SB**, and He D (2018) miR-137 inhibits melanoma cell proliferation through downregulation of GLO1. *Sci China Life Sci* 61: 541-549.

---- 2017----

- 33) **Eichmüller SB, Osen W**, Mandelboim O, and Seliger B (2017) Immune modulatory microRNAs involved in tumor attack and tumor immune escape. *J Natl Cancer Inst.* 109.
- 34) **Das K*, Eisel D*, Lenkl C**, Goyal A, Diederichs S, **Dickes E, Osen W, and Eichmüller SB** (2017) Generation of murine β 2-microglobulin deficient tumor cell lines using the CRISPR/Cas9 system. *PLoS ONE* 12: e0174077.

---- 2016 ----

- 35) **Weber CEM, Luo C**, Hotz-Wagenblatt A, **Gardyan A, Kordaß T**, Holland-Letz T, **Osen W, and Eichmüller SB** (2016) miR-339-3p is a tumor suppressor in melanoma. *Cancer Res* 76: 3562-71.

- 36) Werner S, Chen H, Butt J, Michel A, Knebel P, Holleczeck B, Zörnig I, **Eichmüller SB**, Jäger D, Pawlita M, Waterboer T, and Brenner H (2016) Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. *Scientific Reports*: 6:25467.
- 37) **Kordaß T, Weber CEM**, Oswald M, Ast V, Bernhardt M, Novak D, Utikal J, **Eichmüller SB***, and König R* (2016) SOX5 is involved in balanced MITF regulation in human melanoma cells. *BMC Med Genomics* 9:10.
- 38) Chen H, Werner S, Butt J, Zörnig I, Knebel P, Michel A, **Eichmüller SB**, Jäger D, Waterboer T, Pawlita M, and Brenner H (2016) Prospective evaluation of novel serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. *Oncotarget* 7:16420-32.
- 39) Veyhl-Wichmann M, Friedrich A, Vernaleken A, Singh S, Kipp H, Gorboulev V, Keller T, Chintalapati C, **Pipkorn R**, Pastor-Anglada M, Groll J, and Koepsell H (2016) Phosphorylation of RS1 (RSC1A1) Steers Inhibition of Different Exocytotic Pathways for Glucose Transporter SGLT1 and Nucleoside Transporter CNT1, and an RS1-Derived Peptide Inhibits Glucose Absorption. *Mol Pharmacol* 89: 118-132.
- 40) Komljenovic D, Wiessler M, Waldeck W, Ehemann V, **Pipkorn R**, Schrenk HH, Debus J, and Braun K (2016) NIR-Cyanine Dye Linker: a Promising Candidate for Isochronic Fluorescence Imaging in Molecular Cancer Diagnostics and Therapy Monitoring. *Theranostics* 6: 131-141.

---- 2015 ----

- 41) Lei J, **Osen W, Gardyan A**, Hotz-Wagenblatt A, Gissmann L, **Eichmüller SB**, and Löchelt M (2015) Replication-competent foamy virus vaccine vectors as novel epitope scaffolds for immunotherapy. *Plos One* 10:e0138458.
- 42) Pfirschke C, Gebhardt C, Zörnig I, Pritsch M, **Eichmüller SB**, Jäger D, Enk A, and Beckhove P (2015) T cell responses in early stage melanoma patients occur frequently and are not associated with humoral response. *Cell* 64:1369-81.
- 43) Hao S, **Luo C, Abukiwan A**, Wang G, He J, Huang L, **Weber CEM**, Lv N, Xiao X, **Eichmüller SB***, and He D* (2015) miR-137 inhibits proliferation of melanoma cells by targeting PAK2. *Exp Dermatol*.24:947-952.
- 44) **Gardyan A*, Osen W***, Zörnig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jäger D, and **Eichmüller SB** (2015) Identification of NY-BR-1-specific CD4+ T cell epitopes using HLA-transgenic mice. *Int J Cancer* 136:2588-97.
- 45) Zörnig I, Halama N, Bermejo JL, Ziegelmeier C, **Dickes E**, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, **Eichmüller SB***, and Jäger D* (2015) Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. *Int J Cancer*, 136:138-151.
- 46) Amann PM, Czaja K, Bazhin AV, Rühl R, **Eichmüller SB**, Merk HF, and Baron JM (2015) LRAT overexpression diminishes intracellular levels of biologically active retinoids and reduces retinoid anti-tumor efficacy in the murine melanoma B16F10 cell line. *Skin Pharmacol Physiol*. 28: 205-212.

---- 2014 ----

- 47) Amann PM, Czaja K, Bazhin AV, Rühl R, Skazik C, Heise R, Marquardt Y, **Eichmüller SB**, Merk HF, and Baron JM (2014) Knockdown of lecithin retinol acyltransferase (LRAT) increases all-trans retinoic acid levels and restores retinoid sensitivity in malignant melanoma cells. *Experimental Dermatol.*: 23: 832-837.
- 48) **Schacht T**, Oswald M, Eils R, **Eichmüller SB**, and König R (2014) Estimating the activity of transcription factors by the effect on their target genes. *Bioinformatics*, 30:i401-i407.

- 49) Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Grabowska AK, Vogler I, Diekmann J, Trautwein N, **Eichmüller SB**, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, Deimling Av, Wick W, and Platten M (2014) A vaccine targeting mutant IDH1 induces antitumor immunity. *Nature*, 512: 324-327.
- 50) **Luo C, Weber CEM, Osen W**, Bosserhoff A-K, and **Eichmüller SB** (2014) The role of microRNAs in melanoma. *Eur J Cell Biol* 93: 11-22.

---- 2013 ----

- 51) **Luo C, Merz PR**, Chen Y, **Dickes E**, Pscherer A, Schadendorf D, and **Eichmüller SB** (2013) MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. *Cancer Letters* 341: 240-247.
- 52) Hassel JC, **Amann PM**, Schadendorf D, **Eichmüller SB**, Nagler M, and Bazhin AV (2013) Lecithin/retinol acyltransferase as a potential prognostic marker for malignant melanoma. *Exp Dermatol* 22:757-759.
- 53) Simon-Keller K, Paschen A, Hombach A, Ströbel P, Coindre JM, **Eichmüller SB**, Vincent A, Gattenlöhner S, Hoppe F, Leuschner I, Stegmaier S, Koscielniak E, Leverkus M, Altieri DC, Abken H et al. (2013) Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholin receptor-redirected T cells. *Am J Pathol* 182: 2121-2131.
- 54) **Luo C, Tetteh PW, Merz PR, Dickes E, Abukiwan A**, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schitteck B, Schadendorf D, Diederichs S, and **Eichmüller SB** (2013) miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. *J Invest Dermatol* 133: 768-775.
- 55) Chen Y, Cao L, **Luo C**, Ditzel DAW, Peter J, and Sprengel R (2013) RANGE: Gene transfer of reversibly controlled polycistronic genes. *Molecular Therapy - Nucleic Acids* 2: e85.

---- 2012 ----

- 56) Grund SE, Polycarpou-Schwarz M, **Luo C, Eichmüller SB**, and Diederichs S (2012) Rare Drosha splice variants are deficient in microRNA processing but do not affect general microRNA expression in cancer cells. *Neoplasia* 14: 238-248.
- 57) Bai AH, Milde T, Remke M, Rolli CG, Hielscher T, Cho YJ, Kool M, Northcott PA, Jugold M, **Bazhin AV, Eichmüller SB**, Kulozik AE, Pscherer A, Benner A, Taylor MD, Pomeroy SL, Kemkemer R, Witt O, Korshunov A, Lichter P, and Pfister SM (2012) MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. *Acta Neuropathol* 123: 529-538.
- 58) Abschuetz O*, **Osen W***, Frank K, Kato M, Schadendorf D, and Umansky V (2012) T-cell mediated immune responses induced in ret transgenic mouse model of malignant melanoma. *Cancers* 4: 490-503.
- 59) Savchenko MS, A.Goncharskaia M, Skorikova EE, **Eichmüller SB**, Kushlinsky NE, **Bazhin AV**, and Philippov PP (2012) Autoantibodies Against a Ca²⁺-binding Protein Recoverin in Blood Sera of Patients with Various Oncological Diseases. *Oncology Letters* 3: 377-382.
- 60) **Amann PM, Luo C**, Owen RW, **Hofmann C, Freudenberger M**, Schadendorf D, **Eichmüller SB**, and **Bazhin AV** (2012) Vitamin A metabolism in benign and malignant skin cells: Importance of lecithin/retinol acyltransferase and RPE65. *J Cell Physiol* 227: 718-728.

---- 2011 ----

- 61) **Amann PM, Hofmann C, Freudenberger M**, Holland-Cunz S, **Eichmüller SB**, and **Bazhin AV** (2011) Expression and activity of alcohol and aldehyde dehydrogenases in melanoma cells and in melanocytes. *J Cell Biochem*:113:792-799.
- 62) Meyer C, Sevko A, Ramacher M, **Bazhin AV**, Falk CS, **Osen W**, Borrello I, Kato M, Schadendorf D, Baniyash M, and Umansky V (2011) Chronic inflammation promotes myeloid derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. *PNAS* 108: 17111-17116.
- 63) Colantonio AD, Epeldegui M, **Jesiak M**, Jachimowski L, Blom B, and Uittenbogaart CH (2011) IFN- α Is Constitutively Expressed in the Human Thymus, but Not in Peripheral Lymphoid Organs. *PLoS ONE* 6: e24252.
- 64) **Amann PM, Eichmüller SB**, Schmidt J, and **Bazhin AV** (2011) Regulation of gene expression by retinoids. *Curr Med Chem* 18: 1405-1412.
- 65) **Amann PM**, Schadendorf D, Owen RW, Korn B, **Eichmüller SB**, and **Bazhin AV** (2011) Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaT. *Exp Dermatol* 20: 373-375.

---- 2010 ----

- 66) Simon-Keller K, Paschen A, **Eichmüller S**, Gattenlohner S, Barth S, Koscielniak E, Leuschner I, Stobel P, Hombach A, Abken H, and Marx A (2010) [Adoptive T-cell therapy of rhabdomyosarcoma]. *Pathologe* 31 Suppl 2: 215-220.
- 67) **Osen W, Soltek S**, Song M, Leuchs B, Steitz J, Tüting T, **Eichmüller SB**, Ngyuen XD, Schadendorf D, and Paschen A (2010) Comprehensive screening of human tumor antigens for CD4+ T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries. *PLoS ONE* 5: e14137.
- 68) Galani IE, Wendel M, Stojanovic A, **Jesiak M**, Muller MM, Schellack C, Suri-Payer E, and Cerwenka A (2010) Regulatory T cells control macrophage accumulation and activation in lymphoma. *Int J Cancer* 127: 1131-1140.
- 69) Dummer R, **Eichmüller S**, Gellrich S, Assaf C, Dreno B, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A, Bleuzen P, Bataille V, Derbij A, **Wiedemann N**, Waterboer T, Lusky M, Acres B, and Urosevic-Maiwald M (2010) Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-gamma) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas. *Mol Ther* 18: 1244–1247.
- 70) **Bazhin AV, Kahnert S**, Kimpfler S, Schadendorf D, and Umansky V (2010) Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4(+) T cells. *Mol Immunol* 47: 678-684.